Do-Youn Oh

Do-Youn Oh at Seoul National University is a leading Asian expert in biliary tract cancer who has been principal investigator on multiple pivotal trials including TOPAZ-1, which established durvalumab plus gemcitabine-cisplatin as first-line standard. Her research has characterized molecular features of biliary tract cancers in Asian populations, which show distinct epidemiology with higher prevalence in East Asia. She has contributed to understanding FGFR2 fusions and other targeted alterations in Korean and regional CCA populations. Her work bridges genomic characterization, immunotherapy, and Asian-specific epidemiological considerations in BTC.